Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. It
offers QRX003, a potential therapy for the treatment of Netherton Syndrome; QRX004, a topical lotion for the treatment recessive dystrophic epidermolysis bullosa; and QRX006, a topical lotion to treat rare skin disease. The company was founded in 2018 and is based in Ashburn, Virginia. The company trades on NCM exchange. The company headquarter is located in Ashburn, United States. The company was established in the 2018.
| Ticker | QNRX |
| Long Name | Quoin Pharmaceuticals, Ltd. |
| Short Name | Quoin Pharmaceuticals, Ltd. |